Exclusive Licensing Agreement for GIAPREZA and XERAVA in EuropeLa Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and XERAVA™ (Eravacycline) in Europe
La Jolla to receive upfront cash payment of $22.5 million plus potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments
Under the terms of the exclusive licensing agreement, La Jolla will be entitled to receive: (i) an upfront cash payment of $22.5 million; (ii) potential commercial milestone payments of up to $109.5 million; and (iii) double-digit tiered royalty payments based on net sales of GIAPREZA and XERAVA. In exchange, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the Territories.
finance.yahoo.com
Biopharma
GNCA - Penny Stock 128M Market Cap can show good results in near future. Q3 2020 EPS results IS better compare to Q2 and Q1 2020. Reward can be better compare to Risk.
Institutional Buying also increased. Price can move 2 to 9 USD.
Best
positive prelim data from a Phase 1 study-leukemia treatmentCuris Announces Positive Preliminary Data from Ongoing Phase 1 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Key findings include:
- Marrow blast reductions observed in all evaluable patients (6 patients).
- 6 of 7 patients enrolled remain on study.
- Patients enrolled experienced a median of 3 prior lines of treatment (range 1-4).
- Two patients experienced a marrow complete response, one with blast count going from 23% pretreatment to 1% on treatment, and the other going from 11% pretreatment to 2% on treatment.
- No DLTs observed in 7 DLT-evaluable patients in the 200 mg BID and 300 mg BID cohorts.
- Enrollment has begun in the 400 mg BID cohort.
Curis said its CA-4948 monotherapy in adult patients was well tolerated, has demonstrated signs of biologic activity in the ongoing study and is capable of achieving "relevant levels of drug exposure."
finance.yahoo.com
Solid Biosciences Announces $90 Million Private PlacementSolid Biosciences Announces $90 Million Private Placement
Solid Biosciences has entered into a securities purchase agreement with a select group of institutional investors and accredited investors for a $90 million private placement, which is expected to close on or about December 15, 2020, subject to the satisfaction of customary closing conditions.
The private placement includes new investors Suvretta Capital Management, LLC and Aspire Capital Fund, LLC and existing investors, including RA Capital Management, Perceptive Advisors, LLC, Bain Capital Life Sciences, EcoR1 Capital, LLC, Boxer Capital, and Ikarian Capital, LLC, as well as certain board members and executive officers.
In this private placement, the Company is selling 24,324,320 shares of common stock at a price of $3.70 per share.
The Company expects to use net proceeds from the private placement to fund research and development expenses, including the advancement of SGT-001, and for working capital and other general corporate purposes.
finance.yahoo.com
ridethepig | Long $ABUS for an 80% move...Another single stock opportunity that is worth building a bridge over; $ABUS (Arbutus Biopharma) an excellent and cheap shelter for the next chapter in covid flows.
The beauty of choice! It is interesting as all covid vaccines will have to RNA IP .. this is a convincing driver.
As well as creating a shelter, use the intimately linked highs to add and build more on the position once it starts working. I am looking for an +80% move to the upside over the coming weeks.
Thanks as usual for keeping the feedback coming 👍 or 👎
CHM.C -- Biomedical/Cannabis play trading below cash positionCHM.C is breaking out on record volume!
The company had $4M in cash at the end of May. The enterprise value of CHM is about $8.5M. Options (.06, .10) and warrants (.50, .70) were issued at significantly higher levels than current stock price. Insiders and consultants hold over 35% of the float.
Cannabis sector is starting to wake up a little but it is the Biomedical angle that has me intrigued about CHM. It has acquired a 16.4% stake ImmunoFlex Therapeutics, the company developing products to enhance immunological responsiveness. It is clear that, once released, they will be marketed in the context of COVID-19 pandemic as preventative and immune system strengthening treatments.
While the target date for ImmunoFlex products release was vague (“late Fall 2020”), there are signs that it will come sooner rather than later. On September 28th, ImmunoFlex announced hiring of prominent medical professionals and established a Scientific Advisory Board. I suspect we will be seeing more news very soon.
On the Cannabis side of things, CHM has recently expanded its Sugarleaf cultivation facility in Washington State by ~ 30%. They are also in the early stages of establishing a California-based operation.
[NVAX] Still holding - Novavax is first "safe" COVID vaccineThis proved to the market and world governments that their nanotechnology is superior and that it works. Next stop, flu vaccine. I'm holding.
Disclaimer: Not financial advice. Just my opinion. See my related posts.
Source: www.cnn.com
[NVAX] Novavax: Preliminary studies produce promising resultsPreliminary studies on coronavirus vaccines have produced promising results.
I'm still a believer in their technology. Check out my previous NVAX posts and/or the first one. They have a promising technology that could revolutionize the vaccine industry. We (humanity) are already very behind in how we produce vaccines AKA using chicken eggs. So Novavax will hopefully pave the way for vaccines going forward.
Things to watch even after COVID-19:
- NanoFlu™
- ResVax™
- Recombinant Nanoparticle Vaccine Technology
- Matrix-M™ Adjuvant Technolog
TL;DR - To the moon and (probably) back lol
*Note: This is pure speculation and my own opinion*
NY Times: www.nytimes.com
CNBC: www.cnbc.com
IBIO Is going to the MOONThis is my first analysis ive ever posted, Any thoughts or ideas to bounce off me i would appreciate
pop and drop at open ... vwap watch for dead cat bounce
2.65 lowest i can see it going bouncing off vwap into golden pocket of fib **( i think itll go 3.29 personally ) to much fomo around bio stocks rn
Elliott wave theory @ 2.19,4.03, 3.29,6.43, to around 5.58 (at this point volume and its going parabolic like nvax
Honestly this bi**h may fly to 30 i got 350 shares and holding strong
first floor 3.59
second floor 3.19 watch for head and shoulder drip.. trump will drop news tuesday
third 2.46 ADD rest
[NVAX] Novavax: Update - 1.6 billion funded!I still believe NVAX has a lot of potential and I'll say it again. My idea is clear that its NanoParticle and Matrix-M Adjuvant tech makes it a prime candidate for a COVID-19 vaccines. Even if it doesn't make it first (or ever), it still has major potential for the seasonal influenza (w/ NanoFlu) and its Respiratory Syncytial Virus (RSV) vaccine. Check out my original post that is linked.
Today's News:
1. www.cnbc.com
2. www.fool.com
RXMD - Roll the Dice on the OTC?First off, THIS IS A RISKY BET. I got in at .082 yes... less than a dime. There was news they are doing antibody COVID testing. This got 40M volume x8 its relative volume. Like I said extremely risky. Watch it today and see what happens. Personally I just bought 3000 shares because I don't care if I lose $250 just to see.
finance.yahoo.com
AGEN - Add to watchlist ASAP.Read the news on last two AGEN articles.. approved for FDA and beat the EPS... This is a monthly chart and i can at LEAST see x2 profits ahead.
Theravance Biopharma $TBPH support at 20SMAIt found it support at 20SMA and most likely will continue to rise
Palatin Technologies (PTN) Breakout, retest, potential triple bottom
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.
MTNB - Bullish Weekly - Trade the Zones - Play the TicksI actually trade this for 15-20% gains on deep supply zones. Last time I got in was .51 so not bad if you understand where to buy in. I like the swings in this stock and has some volume. Bullish weekly at least to start off next week. Might fail right away with the resistance and the highs. Just need a solid open above .73. Still not banking on that. Just wanted to share a decent penny stock that if you know where to buy in then you can get some decent returns over and over. At least for now.
"Reasons Why Long-term Faith on Matinas BioPharma Holdings, Inc. (MTNB) Could Pay Off Investors"
investchronicle.com
Novavax (NVAX) - Vaccine Testing - SARS, MERS, SARS-CoV-2 (2019)This is an interesting idea based on outbreaks of SARS, MERS, and SARS-CoV-2 (2019).
Novavax successfully created vaccines for SARS, MERS, and are on track to create one for SARS-CoV-2 (2019) - ir.novavax.com
Vaccine in development for SARS-CoV-2 (2019): seekingalpha.com
Is this a good investment? If the vaccination is successful and/or coronavirus outbreak continues, it could trend upwards significantly.
Disclaimer: This is not financial advice. Just my own opinion based on research.
Important Notes: For your own safety, the CDC recommends you WASH YOUR HANDS FREQUENTLY. COVER YOUR MOUTHS WHEN YOU COUGH/SNEEZE.
Cup and HandleThe chart depicts a classic cup and handle formation. Place a stop buy order slightly above the upper trend line of the handle. There is a risk of missing the trade if the price continues to advance and does not pull back.
TEVA is still undervalued compared to fair value - they reported positive drug trial data in Japan, and had a nice breakout this week.
gl!
There's nowhere else to go...We have a triple rejection of the sub 8.60 price range on the weekly candles, setup doesn't get much better than that. Consolidation has taken longer than expected but what else is new haha.
Pfizer: Wide Moat and Interesting Ichimoku CloudsAfter the massive price drop at the end of July, Pfizer is pivoting its strategy selling Upjohn Unit to a new joint venture with Mylan and focusing on the new BioPharma business (mainly focusing on Ibrance, Xtandi, Inlyta, etc.). The new strategy provides Pfizer with a wide economic moat. I think the market currently undervalues the stock.
The current price is above Ichimoku Green Cloud, and it coincides with the Lagging Span. I will expect a bullish progression of the price in the long term with the market correctly evaluating the new strategy. However, I see a risk of profit-taking in the next sessions anyhow, not so significant to let the stock test the upper support of the green cloud.
Please, note that this analysis applies to long term positions.
Don't forget to support this idea, if you liked it, and to follow me, here on TradingView.
If you have another trading plan, please share in comments!
Investing Fellow
Disclosure: My ideas contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor.
